ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2798

Bone Marrow In Systemic Lupus Erythematosus Patients Contain a Highly Elevated Proportion Of Somatically Mutated, Activated Naive Cells Comprised Of Substantial Clonal Expansions

Jennifer Hom1, Christopher Tipton2, Christopher Fucile3, Bridget Neary1, Chungwen Wei4, F. Eun-Hyung Lee1, Alex Rosenberg3 and Inaki Sanz2, 1Emory University, Atlanta, GA, 2Medicine/Rheumatology, Emory University, Atlanta, GA, 3University of Rochester, Rochester, NY, 4Rheumatology, Emory University, Atlanta, GA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, bone marrow and systemic lupus erythematosus (SLE), Lupus, Plasmablasts

  • Tweet
  • Email
  • Print
Session Information

Title: B cells in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic lupus erythematosus (SLE) is a disease where autoreactive antibodies are produced as a result of abnormal B cell activation and broken self-tolerance. This activation is perhaps most prominently observed in elevated levels of circulating activated cells within the naïve compartment of SLE patients. The origin, diversity, and direct developmental consequences of this elevated activation are largely unclear though. In this study, we use a variety of multi-color flow cytometry panels to isolate and sort specific bone marrow (BM) and circulating B cell populations for immunoglobulin heavy chain (IGH) deep sequencing analysis. By developing a novel program to trace their inter-population relationships through mutational analysis, we aim to further characterize these cells and their contribution to the pathogenesis of SLE.

Methods: Peripheral blood and BM aspirates from healthy donors and volunteers with SLE were collected and sorted using several multi-color flow cytometry panels. The IGH gene was amplified from these cells using multiple sets of VH family-specific and isotype-specific primers. Deep sequencing was conducted using Illumina MiSeq technology, and results were analyzed using an internally developed analysis program that performs quality filtering, detailed mutational analysis, and identification and matching of clonal lineages.

Results: We found that a population of circulating mitotracker green (MTG) positive, CD23- activated naïve cells were highly elevated in flaring SLE patients, slightly elevated in non-flaring patients, and largely absent in healthy controls. This population was also identified in BM of SLE patients, and it was found to be highly elevated in all SLE samples. Deep sequencing analysis showed that unlike most other populations in the circulation and BM, this population was highly oligoclonal, with some clones accounting for greater than 5% of the total population. Sequences from these activated naïve cells were somatically mutated and typically found to be of lower VH mutation rates than memory and plasmablasts (PB), but higher than resting naïve cells. We found clonal relations between several circulating and BM B cell subsets and tracked the lineage maturation using mutation analysis. Surprisingly, the activated naïve fraction was highly related to PB and through mutational tree analysis, they were found to inhabit the more proximal portion of the same lineage branches as the more distal PB.

Conclusion: Our data suggest that in SLE, there is an expansion of activated MTG+, CD23- naive cells which may be an early implication of abnormal B cell activation as a result of damaged self-tolerance. We show that these cells are highly related to circulating and BM antibody-producing PB, which are typically also expanded in SLE.


Disclosure:

J. Hom,
None;

C. Tipton,
None;

C. Fucile,
None;

B. Neary,
None;

C. Wei,

Biogen Idec,

2;

F. E. H. Lee,
None;

A. Rosenberg,
None;

I. Sanz,

Pfizer Inc,

5,

Biogen Idec,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bone-marrow-in-systemic-lupus-erythematosus-patients-contain-a-highly-elevated-proportion-of-somatically-mutated-activated-naive-cells-comprised-of-substantial-clonal-expansions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology